Clinical trial NCT00244985 (phase 1/phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pegylated liposomal doxorubicin hydrochloride
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following indolent or aggressive B-cell non-Hodgkin's lymphoma
             (NHL) subtypes:

               -  Grade 1-3 follicular lymphoma

               -  Mantle cell lymphoma

               -  Small lymphocytic lymphoma

               -  Diffuse large B-cell lymphoma

               -  Diffuse mixed cell lymphoma

               -  Marginal zone lymphoma

          -  Relapsed or refractory CD20-positive disease

          -  Measurable disease

          -  Must have received ≥ 1 but < 4 prior standard chemotherapy regimens

          -  No Burkitt's lymphoma or precursor B-lymphoblastic lymphoma

          -  No CNS lymphoma

        PATIENT CHARACTERISTICS:

        Performance status

          -  Karnofsky 60-100%

        Life expectancy

          -  At least 6 months

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Hemoglobin > 7 g/dL

        Hepatic

          -  AST or ALT < 2 times upper limit of normal (unless due to primary disease)

          -  Bilirubin ≤ 2 mg/dL

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Cardiovascular

          -  LVEF ≥ 50% by MUGA and/or 2-D echocardiogram

          -  No history of New York Heart Association class II-IV cardiac disease

          -  No congestive heart failure

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known HIV positivity

          -  No uncontrolled active bacterial, viral, or fungal infection

          -  No other serious disease that would preclude study participation

          -  No other primary malignancy within the past 5 years except squamous cell or basal cell
             skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Recovered from prior immunotherapy

          -  Prior immunotherapy, including rituximab or other monoclonal antibody, allowed

        Chemotherapy

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy and recovered

          -  No prior doxorubicin (or equivalent anthracycline) at a cumulative dose > 400 mg/m^2

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Nonsteroidal hormones for nonlymphoma-related conditions (e.g., insulin for diabetes)
             allowed

          -  No concurrent corticosteroids except for a transient inflammatory reaction (i.e., skin
             rash or hives)

        Radiotherapy

          -  Recovered from prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  More than 4 weeks since prior major surgery (other than diagnostic surgery) and
             recovered

        Other

          -  No other concurrent antitumor agents

          -  No other concurrent investigational agents